Biotech Values

[Mufaso]

NVO- Novo Nordisk Jumps On Strong Results For New Weight-Loss Drug

Haven't seen tolerability safety data yet but the weight loss is significant. Note this is phase 1 so numbers can skew both directions in larger trials.

https://www.investors.com/news/technology/novo-nordisk-jumps-on-new-weight-loss-drug/?src=A00220

Novo Nordisk (NVO) said early Thursday that itsexperimental oral drug amycretin showed a 13.1% weight loss in participants after 12 weeks in a phase 1 trial. Shares of the Danish drug giant jumped, while rival Eli Lilly (LLY) fell.

Amycretin results easily best the 6% weight-loss for Novo Nordisk's blockbuster Wegovy. Novo Nordisk plans to start a phase 2 trial in the second half of 2024, with results due in early 2026.

Novo Nordisk stock rose 4.5% before the open, signaling a new all-time high. Eli Lilly, which has its own weight-loss drug Zepbound, fell less than 2%. Viking Therapeutics (VKTX), which recently skyrocketed on strong results for its experimental obesity fighter VK2735, declined 4%.